Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Timothy P. Hughes(Royal Adelaide Hospital), Dong‐Wook Kim(The Catholic University of Korea Uijeongbu St. Mary's Hospital), Michael W. Deininger(Versiti Blood Center of Wisconsin), Moshe Talpaz(University of Michigan), Jörge E. Cortes(Augusta University Health), Michael J. Mauro(Memorial Sloan Kettering Cancer Center), Jeroen J. W. M. Janssen(Radboud University Nijmegen), Brian Druker(Oregon Health & Science University), Andreas Hochhaus(Jena University Hospital), Juan Luis Steegmann(Hospital Universitario de La Princesa), Philipp le Coutre(Humboldt-Universität zu Berlin), Yuyan Duan(Novartis (Switzerland)), Florence Hourcade‐Potelleret(Novartis (Switzerland)), David M. Ross(Flinders Medical Centre), Delphine Réa(Institut Bergonié), Oliver G. Ottmann(Cardiff University), David Hynds(Novartis (Switzerland)), Yosuke Minami(The University of Texas MD Anderson Cancer Center), K. Gary J. Vanasse(Novartis (Switzerland)), Christophe Meille(Novartis (Switzerland)), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Hironobu Minami(Kobe University), Massimo Breccia(Policlinico Umberto I), Michael C. Heinrich(VA Portland Health Care System), Jae H. Park(Memorial Sloan Kettering Cancer Center), Fabian Lang(Goethe University Frankfurt), François-Xavier Mahon(Inserm), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Yeow-Tee Goh(Singapore General Hospital), David T Yeung(Royal Adelaide Hospital)
Cited by 464
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k